Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on ...

Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...

Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

Endometrial Cancer is a type of cancer that begins in the lining of the uterus, most commonly affecting postmenopausal women. Rising prevalence due t ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon ...

Shares of Eli Lilly & Co. LLY rallied 1.34% to $771.71 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,296.79 and ...

While Leerink still expects Zoetis to post revenue and earnings growth, it sees the pace decelerating as rivals like Elanco and Merck (NSE: PROR) gain share. The firm forecasts Zoetis EPS growth to ...

Eli Lilly’s stock closed at $771.75, slipping 3.45% and lagging the broader market. The company’s shares fell despite ...

Global Disruptive Behavior Disorders (DBD) Market is valued approximately at USD 14.83 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 3.31% over the forecast period ...